Press Releases

Global Market for Enzyme Inhibitors Will Achieve Nearly $180B by 2022

January 08, 2018

Additional Reports

WELLESLEY, Mass., Jan 08, 2018– The development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. An updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022.

As the patent cliff takes its toll, market growth is expected to result predominantly from new entrants, including PCSK9 (26.2%), PARP (26.8%), PDE4 (21.7%) and integrase (15.3%) inhibitors, as well as new approvals in older categories of kinase, protease and reverse transcriptase inhibitors. Favorable regulatory changes in developed markets, better healthcare practices (e.g., diagnoses and education along with improved infrastructures) in emerging markets and increasing participation of governments across all regions will help the market reduce losses expected from patent expiry, according to the report Global Markets for Enzyme Inhibitors.

Enzyme inhibitors offer therapeutic options for myriad diseases, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.

Research Highlights

  • The presence of big pharmaceutical companies, a developed regulatory and healthcare infrastructure, and stronger intellectual property protection favor growth of the enzyme inhibitors market in the United States.
  • Emerging markets, particularly the Asia-Pacific region, have shown growth potential in recent years due to rising incidences of obesity, diabetes and cardiovascular disorders.
  • The need for affordable and innovative medicines is driving growth in low- and middle-income developing countries.

“The launch of protease inhibitors and novel reverse transcriptase inhibitors proved to be a boon to patients with HCV and HIV/AIDS, respectively,” said senior editor Robert G Hunter, Healthcare, BCC Research. “The protease inhibitors market will decline in the next five years, while the reverse transcriptase inhibitors market will reach $20.7 billion by 2022.”

Patent Expiration of Branded Drugs

The global market for enzyme inhibitors is going through a rough patch. With the entry of generics, some types of enzyme inhibitors have lost billions of dollars. Competition among products has negatively affected sales of many blockbuster drugs. Price constraints and cost containment by low- and middle-income countries are constant slow-down factors for enzyme inhibitors, which are usually high-value drugs.

Editors/reporters requesting analyst interviews should contact steven.cumming@bccresearch.com.

Global Markets for Enzyme Inhibitors( BIO057C )
Publish Date: Dec 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866-285-7215; Email: editorial@bccresearch.com as the source and publisher. Thank you.